Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dactylitis: pathogenesis and clinical considerations.

Paul J Healy1, Philip S Helliwell

  • 1Academic Unit of Musculoskeletal Medicine, University of Leeds, 36 Clarendon Road, Leeds LS2 9NZ, UK.

Current Rheumatology Reports
|September 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial.

Rheumatology (Oxford, England)·2026
Same author

Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.

Annals of the rheumatic diseases·2026
Same author

Introducing the Global Exploration of Psoriatic Arthritis Disease Activity Assessment (EXPLORE-PsA): The First Young-GRAPPA Research Initiative.

The Journal of rheumatology·2026
Same author

Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial.

The Lancet. Rheumatology·2026
Same author

Psoriatic arthritis-evolution of our understanding of the phenotype.

Best practice & research. Clinical rheumatology·2026
Same author

Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative.

Therapeutic advances in musculoskeletal disease·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
Same journal

Management of IgG4-Related Disease.

Current rheumatology reports·2026
See all related articles

Dactylitis, a key feature of psoriatic arthritis (PsA), presents diagnostic challenges. New objective measures and a better understanding of its pathophysiology are needed for consistent assessment and effective treatment of this condition.

Area of Science:

  • Rheumatology
  • Immunology

Background:

  • Dactylitis is a defining characteristic of psoriatic arthritis (PsA).
  • It also occurs in other conditions like reactive arthritis, sarcoidosis, gout, sickle cell disease, and infections.
  • Current definitions and assessments of dactylitis in PsA lack consensus and consistency.

Purpose of the Study:

  • To address the challenges in defining and assessing dactylitis in PsA.
  • To introduce a new objective measure for uniform assessment in clinical trials.
  • To review the pathophysiology and treatment landscape of dactylitis.

Main Methods:

  • Review of existing literature on dactylitis in PsA and other conditions.
  • Discussion of newly developed objective measures for dactylitis assessment.

Related Experiment Videos

  • Analysis of pathophysiological mechanisms including synovitis, tenosynovitis, and enthesitis.

    • Main Results:

    • Dactylitis assessment in PsA is inconsistent, necessitating new objective measures.
    • Pathophysiology varies; in spondyloarthropathies, it involves synovitis, tenosynovitis, and enthesitis, while other conditions have varied mechanisms.
    • Research on PsA dactylitis treatment is limited by few trials and inconsistent outcomes.

    Conclusions:

    • Standardized assessment tools are crucial for advancing PsA dactylitis research.
    • Understanding the diverse pathophysiology is key to targeted treatment strategies.
    • Infliximab is the only drug with robust evidence from randomized controlled trials for treating PsA dactylitis.